Phase 3 trial analyzes overall survival rates by baseline liver function in unresectable hepatocellular carcinoma, suggesting improved outcomes with combined therapy.
Background: In the Phase 3 HIMALAYA study (NCT03298451) in uHCC, STRIDE (Single T Regular Interval D) significantly improved OS versus sorafenib (S) in the primary analysis (Abou-Alfa et al. NEJM Evid 2022) and demonstrated durable long-term survival with a 4-year OS rate of 25.2% (Sangro et al. Ann Oncol 2024). Albumin-bilirubin (ALBI) grade is an objective measure of liver function in HCC. Here, we report a 5-year OS analysis in uHCC and evaluate OS by baseline ALBI grade.
No takes yet. Share an insight, caveat, or question.
Wirth et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: